✦ LIBER ✦

Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer

✍ Scribed by Jie Luo; Ying Xu; Songwen Zhou; Aiwu Li; Di Zheng; Jianfang Xu; Caicun Zhou

Publisher: Springer
Year: 2008
Tongue: English
Weight: 278 KB
Volume: 7
Category: Article
ISSN: 1610-1979
DOI: 10.1007/s10330-008-0062-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Irinotecan and oxaliplatin combination a

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

✍ Myung Hee Chang; Kyoung Ha Kim; Hyun Jung Jun; Hyo Song Kim; Seong Yoon Yi; Ji E 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 312 KB

Cisplatin, doxorubicin, cyclophosphamide

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer

✍ Joseph Aisner; Margaret Y. Whitacre; Daniel R. Budman; Kathy Propert; Gary Strau 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 442 KB

Cisplatin-based combination chemotherapy

Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer

✍ Kaoru Kubota; Kiyoyuki Furuse; Masaaki Kawahara; Nagahisa Kodama; Mitsumasa Ogaw 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 146 KB

Combination of topotecan and etoposide a

Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy

✍ Hye Jin Choi; Byoung Chul Cho; Sang Joon Shin; Seong Ha Cheon; Jong Yul Jung; Jo 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 245 KB

Combination effects of cisplatin, vinore

Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro

✍ Hitoshi Mogi; Yoshinori Hasegawa; Atsushi Watanabe; Fumio Nomura; Hideo Saka; K. 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 694 KB

Combination chemotherapy with cisplatin

Combination chemotherapy with cisplatin and etoposide associated with radiotherapy in the treatment of small-cell lung cancer

✍ F. Figoli; A. Veronesi; M. G. Trovo; D. Errante; M. Della Valentina; V. Zagonel; 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 447 KB

A total of 52 consecutive, previously untreated patients with small-cell lung cancer (SCLC) were scheduled to receive six cycles of a combination of etoposide (75 mg/m2 per day) and cisplatin (20 mg/m2 per day), each cycle given over 5 consecutive days. In all, 28 patients had extensive disease (ED)